Revised adult T-cell leukemia-lymphoma international consensus meeting report

Cook, L. B. and Fuji, S. and Hermine, O. and Bazarbachi, A. and Ramos, J. C. and Ratner, L. and Horwitz, S. and Fields, P. and Tanase, A. and Bumbea, H. and Cwynarski, K. and Taylor, G. and Waldmann, T. A. and Bittencourt, A. and Marcais, A. and Suarez, F. and Sibon, D. and Phillips, A. and Lunning, M. and Farid, R. and Imaizumi, Y. and Choi, I. and Ishida, T. and Ishitsuka, K. and Fukushima, T. and Uchimaru, K. and Takaori-Kondo, A. and Tokura, Y. and Utsunomiya, A. and Matsuoka, M. and Tsukasaki, K. and Watanabe, T. (2019) Revised adult T-cell leukemia-lymphoma international consensus meeting report. Journal of Clinical Oncology, 37 (8). pp. 677-687.

[img] Text
Revised adult T-cell leukemia-lymphoma international consensus meeting report.pdf

Download (1MB)


PURPOSE Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches. METHODS Reflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology—Human T-Lymphotropic Virus and Related Retroviruses—in Tokyo, Japan, March, 2017, to review evidence for current clinical practice and to update the consensus with a new focus on the subtype classification of cutaneous ATL, CNS lesions in aggressive ATL, management of elderly or transplantation-ineligible patients, and treatment strategies that incorporate up-front allogeneic hematopoietic stem-cell transplantation and novel agents. RESULTS As a result of lower-quality clinical evidence, a best practice approach was adopted and consensus statements agreed on by coauthors (. 90 agreement). CONCLUSION This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL Copyright © 2019 American Society of Clinical Oncology. All rights reserved.

Item Type: Article
Additional Information: Cited By :14 Export Date: 16 February 2020 CODEN: JCOND Correspondence Address: Tsukasaki, K.; Department of Hematology, International Medical Center, Saitama Medical University, 1397-1 Yamane, Japan; email:
Uncontrolled Keywords: adult allogeneic hematopoietic stem cell transplantation Article cancer cell cancer immunotherapy cancer prognosis cancer survival clinical practice comprehension cutaneous T cell lymphoma dendritic cell genome analysis human hypercalcemia molecular pathology multidrug resistance opportunistic infection peripheral T cell lymphoma priority journal skin defect survival rate T cell leukemia tumor volume
Subjects: QZ pathology-neoplasms-Genetics
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib1 lib1
Date Deposited: 21 Jun 2020 05:03
Last Modified: 21 Jun 2020 05:03

Actions (login required)

View Item View Item